ALAMEDA, Calif., April 9, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time. A press release with first quarter 2024 financial results will be issued after market close that day.
Webcast & Conference Call Information
The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 7567226), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$273.78 |
| Daily Change: | -2.06 -0.75 |
| Daily Volume: | 631,536 |
| Market Cap: | US$10.510B |
December 30, 2024 October 30, 2024 October 14, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
